Perspective Therapeutics Inc’s recently made public that its Chief Executive Officer Spoor Johan M. acquired Company’s shares for reported $49384.0 on Mar 28 ’25. In the deal valued at $2.24 per share,22,026 shares were bought. As a result of this transaction, Spoor Johan M. now holds 59,383 shares worth roughly $0.11 million.
Then, Spoor Johan M. bought 4,650 shares, generating $10,288 in total proceeds. Upon buying the shares at $2.21, the Chief Executive Officer now owns 4,650 shares.
Before that, Williamson Robert F III bought 38,145 shares. Perspective Therapeutics Inc shares valued at $81,775 were divested by the Director at a price of $2.14 per share. As a result of the transaction, Williamson Robert F III now holds 108,982 shares, worth roughly $0.2 million.
H.C. Wainwright initiated its Perspective Therapeutics Inc [CATX] rating to a Buy in a research note published on March 13, 2025; the price target was $10. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in early March with a ‘”a Sector outperform”‘ rating. BofA Securities also remained covering CATX and has decreased its forecast on November 25, 2024 with a “Neutral” recommendation from previously “Buy” rating. UBS started covering the stock on October 24, 2024. It rated CATX as “a Buy”.
Price Performance Review of CATX
On Friday, Perspective Therapeutics Inc [AMEX:CATX] saw its stock fall -8.16% to $1.80. Over the last five days, the stock has lost -18.18%. Perspective Therapeutics Inc shares have fallen nearly -43.57% since the year began. Nevertheless, the stocks have fallen -87.50% over the past one year. While a 52-week high of $19.05 was reached on 01/24/25, a 52-week low of $1.90 was recorded on 04/04/25. SMA at 50 days reached $2.7906, while 200 days put it at $8.2169.
Levels Of Support And Resistance For CATX Stock
The 24-hour chart illustrates a support level at 1.7533, which if violated will result in even more drops to 1.7067. On the upside, there is a resistance level at 1.8783. A further resistance level may holdings at 1.9567. The Relative Strength Index (RSI) on the 14-day chart is 26.88, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.3119, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.20%. Stochastics %K at 8.83% indicates the stock is a buying.
How much short interest is there in Perspective Therapeutics Inc?
A steep rise in short interest was recorded in Perspective Therapeutics Inc stocks on 2025-03-14, growing by 0.46 million shares to a total of 5.94 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 5.48 million shares. There was a rise of 7.73%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 01, 2024 when Wedbush began covering the stock and recommended ‘”an Outperform”‘ rating along with a $25 price target.
